La cadena de opciones muestra datos clave de las opciones de acciones de DaVita a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para DaVita..

DaVita (NYSE:DVA) Bolsa, Cadena de Opciones

DaVita

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.

DaVita Inc

BrandywineGLOBAL-Dynamic US Large Cap Value ETF

Dovarri Inc

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

WIIM

DaVita shares are trading lower following mixed Q3 earnings.

<h3>Gainers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock increased by 9.9% to $3.33 during Tuesday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 8.82% to $0.37. The company's market cap stands at $2.6 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 6.3% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 5.37% to $0.31. The company's market cap stands at $16.8 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) shares rose 5.33% to $0.74. The company's market cap stands at $9.1 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock rose 5.33% to $31.0. The market value of their outstanding shares is at $1.5 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) shares declined by 11.2% to $15.01 during Tuesday's after-market session. The company's market cap stands at $792.6 million. </li>
<li>DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) stock decreased by 8.25% to $145.25. The market value of their outstanding shares is at $12.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares declined by 7.93% to $2.79. The market value of their outstanding shares is at $7.0 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares decreased by 7.7% to $0.28. The market value of their outstanding shares is at $3.7 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 7.09% to $5.51. The market value of their outstanding shares is at $2.7 million. </li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock decreased by 6.59% to $14.75. The market value of their outstanding shares is at $1.7 billion. The company's, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABVC

APVO

ATRC

CYCN

LGMK

MRNS

RSLS

SNES

TYRA

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

News

Guidance

Sees FY24 Adj. EPS $9.25-$10.05, Free Cash Flow $950M-$1.2B

DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) reported quarterly earnings of $2.59 per share which missed the analyst consensus estimate of $2.73 by 5.13 percent. The company reported quarterly sales of $3.264 billion which beat the analyst consensus estimate of $3.247 billion by 0.50 percent. This is a 4.57 percent increase over sales of $3.121 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

DaVita Q3 2024 Adj. EPS $2.59 Misses $2.73 Estimate, Sales $3.264B Beat $3.247B Estimate

DaVita, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) has witnessed strong momentum year to date, with its shares up 47.3% compared with the&nbsp;industry&#39;s&nbsp;growth of 14.8%. The S&amp;P 500 composite has risen 19.5% in the same period.
DaVita,&nbsp;carrying a Zacks Rank #2 (Buy) at present, is witnessing an upward trend in its stock price, prompted by the company&#39;s business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.
DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/39/80935.jpg?v=255633029" />
Image Source: Zacks Investment Research
<h2>Catalysts Driving DaVita&#39;s Growth</h2>
The rally in the company&#39;s share price can be attributed to the strength of its dialysis and related lab services. The optimism led by a solid second-quarter 2024 performance and robust business potential are expected to contribute further.
DaVita is experiencing significant growth driven by its patient-centric care approach, leveraging its kidney care services platform to offer a wide range of treatment models and modalities. The increasing prevalence of value-based partnerships in kidney health enables nephrologists, physicians, and transplant programs to collaborate more effectively, enhancing the understanding of individual patient needs and facilitating improved care coordination and early interventions.
A key element of DaVita&#39;s growth strategy is the acquisition of dialysis centers and related businesses, as evident from the recent extension of its pilot phase for a supply and collaboration agreement with Nuwellis. Upon completion of this phase, which ends on Aug. 31, 2024, DaVita may extend the agreement for the ongoing provision of inpatient and outpatient ultrafiltration services for up to 10 years.
The company&#39;s global market share is also on the rise, with recent agreements to expand operations into Brazil, Colombia, Chile and Ecuador.
In the second quarter of 2024, DaVita reported results that exceeded expectations, showcasing a positive trend in both revenue streams and patient services. The sequential increase in daily United States dialysis treatments and the opening of new centers, along with acquisitions overseas, indicates a strong growth trajectory.
Furthermore, DaVita has raised its earnings projections for fiscal 2024, now forecasting adjusted EPS in the range of $9.25 to $10.05, up from the prior range of $9 to $9.80, which is likely to attract further interest from investors.
<h2>Risk Factor</h2>
DaVita faces a risk of reduced profitability if patients shift from commercial insurance to government programs, as government reimbursement rates are significantly lower. This shift could be triggered by rising unemployment, impacting DaVita&#39;s revenues and profit margins.
<h2>A Look at Estimates</h2>
The Zacks Consensus Estimate for DaVita&#39;s 2024 and 2025 bottom line projects an 18% and 14.4% year-over-year improvement, respectively, to earnings of $9.99 and $11.42 per share.
In the past 30 days, the Zacks Consensus Estimate for the company&#39;s 2024 earnings has remained constant at $9.99 per share.
Revenues for 2024 and 2025 are anticipated to rise 5.4% and 4%, respectively, to $12.8 billion and $13.3 billion on a year-over-year basis.
<div class="chart_embed">
<h3>DaVita Inc. Price</h3>
<img alt="DaVita Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2b/1728478167.png" style="height:251px; width:544px" title="" />
DaVita Inc. price | DaVita Inc. Quote
</div>
<h2>Other Key Picks</h2>
Some other top-ranked stocks in the broader medical space are Rockwell Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmti#NASDAQ">RMTI</a>), Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>). While Rockwell Medical carries a Zacks Rank #1 (Strong Buy), Quest Diagnostics&nbsp;and RadNet carry a Zacks Rank #2 each at present.
Rockwell Medical&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average being 87.9%.
RMTI&#39;s shares have gained 79.7% compared with the industry&#39;s 10.7% growth year to date.
Quest Diagnostics&nbsp;has an estimated long-term growth rate of 6.8%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics&nbsp;has gained 7.9% compared with the industry&#39;s 14.9% growth year to date.
RadNet&#39;s&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.
RDNT&#39;s shares have gained 93.7% year to date compared with the industry&#39;s&nbsp;14.8% growth.
<a href="https://www.zacks.com/stock/news/2348406/davita-stock-gains-47-3-year-to-date-what-s-behind-the-rally?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2348406">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

RDNT

RMTI

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

AMN Healthcare Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amn#NYSE">AMN</a>) launched an innovative technology suite, WorkWise, last Wednesday. The suite is expected to unify the company&#39;s technologies into one single technology offering.
Per AMN Healthcare, WorkWise has been designed to streamline workforce processes by combining the capabilities of quantifying staffing demand with predictive scheduling, automated workforce management and enhanced clinician engagement using AI technology. The technology suite will likely empower healthcare systems to efficiently source the appropriate talent, while effectively managing costs.
The latest launch is expected to significantly boost AMN Healthcare&#39;s Technology and Workforce Solutions business and solidify its foothold in the healthcare space.
<h2>Likely Trend of AMN Stock Following the News</h2>
Following the announcement on Oct. 2, shares of the company moved nearly 2.8% south to $38.64 at yesterday&#39;s close.
Historically, the company has gained a high level of synergies from its product launches. Although the latest launch is likely to be beneficial for AMN&#39;s top-line growth going forward, the stock declined overall since the announcement despite a slight gain yesterday.
AMN Healthcare currently has a market capitalization of $1.47 billion. It has an earnings yield of 8.3%, higher than the industry&#39;s 3.6%. In the last reported quarter, AMN delivered an earnings surprise of 30.7%.
<h2>Significance of the Launch of AMN Healthcare&#39;s WorkWise</h2>
Per AMN Healthcare, WorkWise is completely integrated with healthcare organizations&#39; internal systems. This is expected to enable hospitals to optimize personnel for any type of job (permanent, per diem, contract), sourcing from internal and external talent, to reduce costs and predict staffing needs with greater precision. The solution will likely leverage automation and data analysis to provide insights and build engaged talent networks for effective workforce management and increased speed-to-fill for staffing needs.
AMN Healthcare&#39;s management believes that WorkWise will be an integrated solution with multiple capabilities that can work together to address complex workforce challenges in the healthcare industry. It is expected to provide a full end-to-end solution for hospitals and healthcare systems, which is built to adapt and evolve with their needs.
<h2>Industry Prospects in Favor of AMN</h2>
Per a report by Grand View Research, the global healthcare workforce management system market was valued at $1.9 billion in 2023 and is anticipated to witness a CAGR of 13.2% between 2024 and 2030. Factors like the shift toward value-based reimbursements and the increasing adoption of telehealth technologies and AI-driven analytics are likely to drive the market.
Given the market potential, the latest launch will likely provide a significant impetus to AMN Healthcare&#39;s business.
<h2>AMN Healthcare&#39;s Notable Launches</h2>
In August, AMN Healthcare launched Strategic Partnership Solutions. It aims to transform language access programs in healthcare organizations by providing comprehensive language services and strategic support to organizations.
In July, AMN Healthcare introduced a new teletherapy platform, Televate. Per the company, it has been designed to increase access to therapy services for students nationwide.
<h2>AMN&#39;s Share Price Performance</h2>
Shares of the company have lost 50.7% in the past year against the industry&#39;s 7.5% rise and the S&amp;P 500&#39;s 30.9% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/04/80821.jpg?v=2132398298" />
Image Source: Zacks Investment Research
<h2>AMN Healthcare&#39;s Zacks Rank &amp; Key Picks</h2>
Currently, AMN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Baxter International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>) and Boston Scientific Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).
DaVita, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%.
DaVita&#39;s shares have gained 74.8% compared with the industry&#39;s 31.7% rise in the past year.
Baxter, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10%. BAX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 0.7% compared with the industry&#39;s 22.9% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 62.4% compared with the industry&#39;s 22.9% rise in the past year.
<a href="https://www.zacks.com/stock/news/2347765/amn-stock-down-despite-workwise-launch-to-enhance-healthcare-delivery?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347765">To read this article on Zacks.com click here.</a>

Offerings

Management

Tech

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

In the last three months, 5 analysts have published ratings on DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $162.0, a high estimate of $175.00, and a low estimate of $145.00. Witnessing a positive shift, the current average has risen by 6.3% from the previous average price target of $152.40.
<img src="https://www.benzinga.com/files/images/story/2024/1728309618_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of DaVita among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$145.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$150.00</td>
<td>$139.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DaVita. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DaVita compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of DaVita's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DaVita's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DaVita analyst ratings.</a>
<h2>Unveiling the Story Behind DaVita</h2>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
<h3>Financial Milestones: DaVita's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: DaVita displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.21%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DaVita's net margin is impressive, surpassing industry averages. With a net margin of 6.99%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): DaVita's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 28.57%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): DaVita's ROA stands out, surpassing industry averages. With an impressive ROA of 1.29%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: DaVita's debt-to-equity ratio stands notably higher than the industry average, reaching 18.45. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About DaVita Stock

Truist Securities analyst David Macdonald maintains DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) with a Hold and raises the price target from $165 to $175.

Price Target

Truist Securities Maintains Hold on DaVita, Raises Price Target to $175

Javier Rodriguez, Chief Executive Officer at DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), reported an insider sell on September 17, according to a new SEC filing. 
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000927066/000092706624000165//Archives/edgar/data/927066/000092706624000165/0000927066-24-000165-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Rodriguez sold 59,881 shares of DaVita. The total transaction value is $9,861,636.
Tracking the Wednesday's morning session, DaVita shares are trading at $161.38, showing a down of 1.73%.
<h3>All You Need to Know About DaVita</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
<h3>Breaking Down DaVita's Financial Performance</h3>
Revenue Growth: DaVita's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.21%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 32.77%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): DaVita's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.56.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 18.45, caution is advised due to increased financial risk.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 17.47 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.2 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): DaVita's EV/EBITDA ratio, lower than industry averages at 9.82, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000927066">Check Out The Full List Of DaVita's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Executive Officer Of DaVita Sold $9.86M In Stock

DaVita shares are trading higher after the company appointed David Maughan as COO.

DaVita Appoints David Maughan As Chief Operating Officer, Effective Sept. 15

Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The strength in the iStent product line and solid execution across its global glaucoma and Corneal Health franchises augur well.
The sustained recovery trends across segments and solid business prospects in spite of the pandemic-induced uncertainties raise optimism. Recent strategic alliances instill confidence in the stock.
The company is also engaged in boosting its portfolio through the development of new products. It currently has seven clinical-stage trials and another three preclinical development programs underway. A number of these pipeline programs are in active pivotal clinical trials, including iLution Travoprost, iDose ROCK and iDose TREX.
The company&#39;s shares have risen 58.2% year to date compared with the industry&#39;s 8.4% growth. The rally was primarily driven by top-line growth in the past few quarters. The S&amp;P 500 Index was up 14.4% in the same time frame.
However, stiff competition in the medical device industry and vendor uncertainty are other headwinds. Meanwhile, a stringent regulatory approval process for the iDose platform and products is a woe.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b6/77271.jpg?v=801173257" />
Image Source: Zacks Investment Research
<h2>GKOS&#39; Products Driving Strong Business Performance</h2>
During the second quarter, GKOS&#39; glaucoma franchise witnessed growth in revenues, driven by its iStent portfolio, coupled with growing contributions from iDose TR. The company commenced the initial phases of the controlled launch plan for iDose TR during the reported quarter.
Per the second-quarter 2024 earnings call, iStent continued to demonstrate robust demand with positive surgeon feedback. This primarily highlights its three-stent solution favorable safety profile and streamlined injector system. The company&#39;s continued advancement in key market access initiatives for iStent infinite looks promising.
Continued strong demand across international glaucoma and Corneal Health franchises should be the key top-line drivers in 2024. Moreover, the commercial launch of iStent Infinite in 2023 is boosting the U.S. glaucoma franchise, which should drive growth in the upcoming few quarters.
The unique permanent J-code for iDose TR became effective from July 1. This is likely to increase patient access, driving sales growth in the upcoming quarters. The franchise also benefited from rapid international expansion.
<h2>Clinical Progress Drives GKOS&#39; Prospects</h2>
Clinical trials are the primary means to evaluate the efficacy and safety of new medical technologies.
Glaukos is currently developing several pipeline products, namely iDose TREX, iDose ROCK and iLution Travoprost. These next-generation extended-release candidates are in different stages of clinical development. Successful development, followed by a potential launch of these products, should boost Glaukos&#39; glaucoma portfolio.
The iDose TR candidate received the FDA approval in December 2023. The candidate, a targeted injectable implant, demonstrated tolerability and a favorable safety profile through 12 months in a late-stage clinical study.
Glaukos is also evaluating iLink system using Epioxa therapy for the treatment of keratoconus without the removal of the epithelium in a phase III study. The company has already completed one phase III study in 2021 on iLink. A potential new drug application is expected to be filed by the end of 2024.
The company commenced three new clinical trials during the fourth quarter of 2023 &mdash; a PMA clinical trial for iStent infinite in mild-to-moderate glaucoma patients; a Phase 2a study for iLution Travoprost; and a first-in-human clinical development program for GLK-401, an intravitreal multi-kinaseinhibitor retinal program for wet AMD patients. The company plans to start a phase 3 study for iDose TREX later in 2024 and complete enrollment in Phase 2 trials for its iLink third-generation therapy.
<h2>International Market Holds Potential for GKOS</h2>
Apart from the U.S. market, Glaukos is also focusing on expanding on a global scale. The company has been developing a sales base and increasing its marketing and market access efforts. It currently sells its products primarily through direct sales subsidiaries in 17 countries and independent distributors in certain nations.
GKOS&#39; continued efforts to scale its international infrastructure and execute the plans to position MIGS as a standard of care in each region and every major market in the world will likely boost glaucoma revenues going forward. The company&#39;s efforts have been positively impacting its international growth.
In the fourth quarter of 2023, the company&#39;s Glaucoma sales were up more than 25%. Corneal Health sales improved 19% in international markets. Continued broad-based growing demand in many key international markets for combined cataract and glaucoma procedures is likely to continue in the upcoming few quarters.
<h2>Factors Hurting the Stock</h2>
Glaukos&#39; competitors include medical companies, academic and research institutions, and others that develop new drugs, therapies, medical devices or surgical procedures to treat glaucoma. Thus, intense competition continues to weigh on the company&#39;s overall performance.
GKOS currently relies on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models and other pipeline products. If any one or more of these suppliers cease to provide the company with sufficient quantities of components or drugs in a timely manner or on acceptable terms, it would have to seek alternate sources of supply.
Additionally, some of the vendors continue to experience challenges pertaining to supply of raw materials and labor shortages. As a result of these supply chain challenges and current inflationary pressures, Glaukos has experienced higher costs for certain components and raw materials. These setbacks are likely to remain for the rest of 2024, albeit at a slower pace.&nbsp;
<div class="chart_embed">
<h3>Glaukos Corporation Price</h3>
<img alt="Glaukos Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/0f/1726048478.png" style="height:251px; width:575px" title="" />
Glaukos Corporation price | Glaukos Corporation Quote
</div>
<h2>GKOS&#39; Zacks Rank &amp; Stocks to Consider</h2>
Glauos currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Quest Diagnostics Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and Boston Scientific Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%.
DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%. Its shares have risen 56.9% compared with the industry&#39;s 27.5% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.
Quest Diagnostics&#39; shares have risen 21.6% compared with the industry&#39;s 27.5% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 50.8% compared with the industry&#39;s 17.2% growth in the past year.
<a href="https://www.zacks.com/stock/news/2334519/glaukos-stocks-rides-on-strong-product-demand-amid-competition?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2334519">To read this article on Zacks.com click here.</a>

Biotech

GKOS

Glaukos Stocks Rides on Strong Product Demand Amid Competition

Patterson Companies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdco#NASDAQ">PDCO</a>) is well poised for growth in the coming quarters, courtesy of its broad product line. The optimism, led by a strong performance of certain business segments during first-quarter fiscal 2024 and a few notable acquisitions, is expected to contribute further. Integration risks and stiff competitive forces persist.
Shares of this Zacks Rank #3 (Hold) company have lost 24.6% in the past year compared with the industry&#39;s 6.1% decline. The S&amp;P 500 Index has increased 5.9% during the same time frame.
The renowned global dental and animal health company has a market capitalization of $1.82 billion. It projects 5.9% growth for the next five years and expects to maintain its strong performance going forward. Patterson Companies&#39; earnings missed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average negative surprise of 10.78%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/66/77100.jpg?v=775213013" />
Image Source: Zacks Investment Research
Let&#39;s delve deeper.
<h2>Upsides</h2>
Broad Product Spectrum: We are optimistic about Patterson Companies&#39; wide range of consumable supplies, equipment and software, and value-added services. A notable offering from PDCO is a private-label brand named Pivotal. It continues to add stock-keeping units to its broader private-label portfolio. The company&#39;s NaVetor is an integrated cloud-based veterinary practice management software for its Animal Health segment.
In June, PDCO launched new integrations for DentalXChange to provide additional electronic insurance processing and electronic patient statement solutions. In May, it announced a new product, Patterson CarePay+, to provide dental offices with software solutions for patient financing, dental insurance plans and payment processing.
Acquisitions &amp; Alliance: We are upbeat about PDCO&#39;s strategy of expanding its business via strategic acquisitions. In July, Patterson Dental Canada collaborated with Pearl to expand its Second Opinion AI disease detection capabilities&#39; reach in the Canadian dental market. By integrating Second Opinion within Patterson Dental Canada&#39;s leading software platforms, such as Eaglesoft, Fuse and Dolphin, the partnership aims to elevate the standard of dental care across North America.
During 2023, Patterson Companies completed its acquisition of the Texas-based companies, Veterinary Practitioners and Animal Care Technologies, which provide innovative solutions to veterinary practices through data extraction and conversion, staffing and video-based training services. In 2022, the company announced the acquisition of substantially all the assets of Dairy Tech, Inc., which provides pasteurizing equipment and single-use bags.
Fulfillment Facility Modernization to Optimize Supply: PDCO started strategic modernization of its existing fulfillment facilities and capabilities. It is adding new technologies, such as robots, to automate order picking and enhance the fulfillment pace.
PDCO is also focusing on expanding its fulfillment capacity by opening next-generation centers across several countries that will help build sustainable and more efficient channel capabilities. The company&#39;s strategic investments in fulfillment centers should help alleviate capacity constraints, boost distribution capabilities and enhance growth.
To support its facility modernization and expansion, PDCO has allocated $51.2 million in capital spending during fiscal 2024. The amount has increased 20.8% from the prior-year level.
Strong Q1 Results: Patterson Companies&#39; revenues and earnings missed estimates in the first quarter of fiscal 2024, reflecting the negative impact of a cybersecurity attack on its claims processing vendor, Change Healthcare. The impact is likely to alleviate in the upcoming quarters, potentially improving the top and bottom-line performance. Continued growth in the production animal business supported sales in the Animal Health segment.
PDCO has been making significant investments in developing its software and value-added services offerings across both its Dental and Animal Health segments. These are likely to drive the demand for its products.
<h2>Downsides</h2>
Stiff Competition: The U.S. dental products distribution industry is highly competitive and consists chiefly of national, regional and local full-service and mail-order distributors. Patterson Companies needs to continue to introduce newer products in the market to withstand competitive pressure. Failure to do so can dilute its market share.
Integration Risks: PDCO has been on an acquisition spree, which is improving its revenue opportunities but aggravating integration risks. Regular acquisitions are also a distraction for management and are likely to impact organic growth. This may limit the company&#39;s future expansion initiatives and worsen its risk profile.
<div class="chart_embed">
<h3>Patterson Companies, Inc. Price</h3>
<img alt="Patterson Companies, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/d7/1725957492.png" style="height:251px; width:572px" title="" />
Patterson Companies, Inc. price | Patterson Companies, Inc. Quote
</div>
<h2>Estimate Trend</h2>
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $6.62 billion, indicating a 0.8% increase from the previous year&#39;s level. The consensus mark for adjusted earnings per share is pinned at $2.33, implying a 1.3% year-over-year improvement.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Quest Diagnostics Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and Boston Scientific Corporation.
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%.
DaVita&#39;s shares have risen 56.9% compared with the industry&#39;s 27.5% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.
Quest Diagnostics&#39; shares have risen 21.6% compared with the industry&#39;s 27.5% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 50.8% compared with the industry&#39;s 17.2% growth in the past year.
<a href="https://www.zacks.com/stock/news/2334054/here-s-why-you-should-retain-pdco-stock-in-your-portfolio-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2334054">To read this article on Zacks.com click here.</a>

Financing

PDCO

Here's Why You Should Retain PDCO Stock in Your Portfolio for Now

A substantial insider sell was reported on August 28, by Javier Rodriguez, Chief Executive Officer at DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), based on the recent SEC filing.
What Happened: Rodriguez's decision to sell 40,119 shares of DaVita was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000927066/000092706624000154//Archives/edgar/data/927066/000092706624000154/0000927066-24-000154-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $6,255,891.
In the Thursday's morning session, DaVita's shares are currently trading at $154.56, experiencing a up of 0.64%.
<h3>Delving into DaVita's Background</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
<h3>A Deep Dive into DaVita's Financials</h3>
Revenue Growth: DaVita's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.21%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 32.77%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): DaVita's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.56.
</li>
</ul>
Debt Management: DaVita's debt-to-equity ratio surpasses industry norms, standing at 18.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: DaVita's P/E ratio of 16.34 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.12 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 9.47, DaVita could be considered undervalued.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000927066">Check Out The Full List Of DaVita's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sell Alert: Javier Rodriguez Cashes Out $6.26M In DaVita Stock

A substantial insider sell was reported on August 22, by Javier Rodriguez, Chief Executive Officer at DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), based on the recent SEC filing.
What Happened: Rodriguez's decision to sell 334,166 shares of DaVita was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000927066/000092706624000152//Archives/edgar/data/927066/000092706624000152/0000927066-24-000152-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $50,850,040.
DaVita shares are trading up 0.76% at $153.51 at the time of this writing on Friday morning.
<h3>Get to Know DaVita Better</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
<h3>Understanding the Numbers: DaVita's Finances</h3>
Revenue Growth: DaVita's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.21%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 32.77%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): DaVita's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 2.56.
</li>
</ul>
Debt Management: DaVita's debt-to-equity ratio is notably higher than the industry average. With a ratio of 18.45, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 16.21 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 1.11, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): DaVita's EV/EBITDA ratio at 9.43 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000927066">Check Out The Full List Of DaVita's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Javier Rodriguez Executes Sell Order: Offloads $50.85M In DaVita Stock

Alcon, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alc#NYSE">ALC</a>) delivered core earnings per share of 74 cents in the second quarter of 2024, up 7.2% from the year-ago quarter&#39;s figure (up 15% at the constant exchange rate or CER). The figure came in line with the Zacks Consensus Estimate.
Alcon reports &lsquo;core&#39; results based on non-IFRS (International Financial Reporting Standards) measures. In the second quarter, the company&#39;s diluted EPS was 45 cents, up 32.4% year over year.
<h3>Revenues in Detail</h3>
Alcon&#39;s net sales to third parties in the second quarter were $2.48 billion, which missed the Zacks Consensus Estimate by 1.4%. However, the top line increased by 3.3% from the year-ago quarter&#39;s levels (up 6% at CER).
<h3>Quarter in Detail</h3>
Alcon reports operations through two segments &mdash; Surgical (comprising Implantables, Consumables and Equipment/Other) and Vision Care (comprising Contact Lenses and Ocular Health).
Surgical
In the second quarter of 2024, Surgical sales amounted to $1.42 billion, up 3% year over year and 6% at CER. Our model projected the segment&#39;s growth to be 3.5% versus the prior year.
Within this, net sales in Implantables increased 6%, led by the demand for advanced technology intraocular lenses in international markets. Our model projected 3.1% year-over-year growth.
Consumables increased 3%, mainly driven by cataract and vitreoretinal consumables, particularly in international markets, and price increases. Our model&#39;s projection was an increase of 4.9%.
<div class="chart_embed">
<h3>Alcon Price, Consensus and EPS Surprise</h3>
<img alt="Alcon Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/dc/1724230877.png" style="height:265px; width:576px" title="" />
Alcon price-consensus-eps-surprise-chart | Alcon Quote
</div>
Equipment/Other was down 3% from the prior-year quarter&#39;s levels. Our model forecast stood at 0.1% growth.
Vision Care
The segment reported total sales of $1.11 billion, up 7% year over year on a reported basis and 10% at CER. Our model&#39;s projection was 6.7% growth.
Net sales of Contact Lenses increased 9% year over year, driven by product innovation, including toric multifocal modalities and price increases. This surpassed our model&#39;s projected growth of 8% year over year.
Ocular Health sales increased 5% year over year, primarily driven by the portfolio of eye drops, including continued strength from the Systane family of artificial tears. Our model forecast was 4.9%.
<h3>Margins</h3>
The cost of net sales in the second quarter was $1.12 billion, up 5.9% year over year. The core gross profit rose 0.8% to $1.37 billion in the reported quarter. Meanwhile, the core gross margin contracted 123 basis points (bps) to 55.1% in the second quarter of 2024.
SG&amp;A expenses increased 0.6% year over year, while R&amp;D expenses rose 1.4% year over year. The core operating margin fell 26 bps in the second quarter to 12.7%.
<h3>Financial Position</h3>
Alcon exited the second quarter of 2024 with cash and cash equivalents of $1.37 billion compared with $1.14 billion at the end of the first quarter.
The cumulative net cash flow from operating activities at the end of the second quarter was $871 million compared with $410 million in the year-ago period. Free cash flow totaled $667 million at the end of the second quarter of 2024 compared with $189 million in the comparable 2023 months.
<h3>2024 Outlook</h3>
Alcon reiterated its financial outlook for 2024.
The company anticipates 2024 net sales in the range of $9.90-$10.10 billion (unchanged), indicating growth of 7%-9% at CER from 2023. The Zacks Consensus Estimate for ALC&#39;s revenues is pegged at $9.94 billion.
Core EPS for the full year is expected in the range of $3.00-$3.10 (same as earlier). This suggests growth of 15%-18%% at CER from the 2023 levels. The Zacks Consensus Estimate for Alcon&#39;s 2024 earnings is currently pegged at $3.05 per share.
<h3>Our Take</h3>
Alcon closed the second quarter of 2024 with in-line earnings, while revenues missed estimates. On a positive note, the top line improved on a year-over-year basis. The performance was driven by robust demand for the company&#39;s innovative products, balanced geographic footprint and strong execution by the team. Growth in the Vision Care segment underscores the strength of contact lenses.
In June 2024, Alcon&#39;s innovations from the highly anticipated UNITY portfolio, Vitreoretinal Cataract System and Cataract System, secured the FDA&#39;s 510(k) clearance. In the second half of the year, Alcon is preparing for product launches that are set to drive its next phase of growth in 2025 and beyond.
Meanwhile, the contraction of both margins in the quarter is discouraging.
<h3>Zacks Rank and Other Key Picks</h3>
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical, DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) and Veracyte (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>).
Intuitive Surgicalreported a third-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has an estimated long-term earnings growth rate of 16.8% in 2024 compared with the industry&#39;s 11.8%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 8.97%.
DaVita, sporting a Zacks Rank #1, reported second-quarter 2024 adjusted earnings of $2.59, which surpassed the Zacks Consensus Estimate by 4.9%. Revenues of $3.19 billion topped the Zacks Consensus Estimate by 0.7%.&nbsp;
DVA has an estimated long-term earnings growth rate of 17.5% compared with the industry&#39;s 12.4%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 24.2%.
Veracyte, sporting a Zacks Rank #1, reported second-quarter diluted earnings of 30 cents per share compared with the Zacks Consensus Estimate of a loss of 3 cents. Revenues of $114.4 million exceeded the Zacks Consensus Estimate by 14%.
VCYT has an estimated 2024 earnings growth rate of 112.8% compared with the industry&#39;s 11.8%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 328.4%.
<a href="https://www.zacks.com/stock/news/2324779/alcon-alc-q2-earnings-meet-estimates-revenues-increase-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2324779">To read this article on Zacks.com click here.</a>

VCYT

Alcon Q2 Earnings Meet Estimates, Revenues Increase Y/Y

Avantor, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avtr#NYSE">AVTR</a>) recently signed a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively known as Clinical Services), to Audax Private Equity (Audax). The transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.
The clinical services business is currently part of Avantor&#39;s Laboratory Solutions segment.
Avantor&#39;s management plans to discuss the divestiture on its third-quarter 2024 earnings conference call.
The divestiture is expected to enable the company to enhance its focus on strategic growth opportunities in its lab and production businesses while strengthening its balance sheet.
<h3>Rationale Behind the Divestiture</h3>
Avantor expects the transaction to result in approximately $475 million in after-tax cash proceeds and a reduction of approximately $50 million in capitalized leases. Management intends to utilize the after-tax proceeds for debt paydown, which will likely strengthen the company&#39;s balance sheet and reduce interest expenses.
Per management, the agreement is an important step for Avantor as it continues to optimize its portfolio in line with its new operating model. The deal is expected to accelerate its ongoing business transformation and sharpen the company&#39;s strategic focus.
<h3>Industry Prospects</h3>
Per a report by Future Market Insights, the global analytical laboratory service market is valued at $472.6 million in 2024 and is projected to be worth $1,375 million by 2034 at a CAGR of 11.3%. Factors like the growing popularity of point-of-care testing and the increasing adoption of smart lab infrastructure with sensor networks are likely to drive the market.
Given the market potential, the latest divestiture will likely provide a significant impetus to Avantor&#39;s lab and production businesses.
<h3>Notable Development</h3>
Last month, Avantor reported its second-quarter 2024 results, wherein it registered an improved mix from increased bioprocessing revenues. This, along with the accelerated impact of its cost transformation initiative, drove more than 100 basis points of sequential adjusted EBITDA margin expansion during the quarter.
<h3>Price Performance</h3>
Shares of Avantor have gained 15.1% in the past year compared with the 7.9% rise of the industry and 26.3% growth of the S&amp;P 500.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d2/74619.jpg?v=49806369" />
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Key Picks</h3>
Currently, Avantor carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Quest Diagnostics Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and Boston Scientific Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 17.5%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%.
DaVita&#39;s shares have gained 47.5% compared with the industry&#39;s 20.4% rise in the past year.
Quest Diagnostics, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics has gained 13.9% compared with the industry&#39;s 20.4% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 55.2% compared with the industry&#39;s 11.1% rise in the past year.
<a href="https://www.zacks.com/stock/news/2323844/avantor-avtr-inks-deal-to-optimize-portfolio-reduce-debt?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2323844">To read this article on Zacks.com click here.</a>

AVTR

Avantor Inks Deal to Optimize Portfolio, Reduce Debt

DAVID MICHAEL STAFFIERI, Chief Operating Officer at DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), executed a substantial insider sell on August 19, according to an SEC filing.
What Happened: STAFFIERI's decision to sell 42,119 shares of DaVita was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000927066/000092706624000150//Archives/edgar/data/927066/000092706624000150/0000927066-24-000150-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value of the sale is $6,323,507.
The latest market snapshot at Tuesday morning reveals DaVita shares down by 1.7%, trading at $149.59.
<h3>About DaVita</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
<h3>DaVita's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining DaVita's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.21% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 32.77%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): DaVita's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.56.
</li>
</ul>
Debt Management: DaVita's debt-to-equity ratio is notably higher than the industry average. With a ratio of 18.45, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: DaVita's P/E ratio of 16.19 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.11, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): DaVita's EV/EBITDA ratio, lower than industry averages at 9.42, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000927066">Check Out The Full List Of DaVita's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DaVita Chief Operating Officer Trades $6.32M In Company Stock

Truist Securities analyst David Macdonald maintains DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) with a Hold and raises the price target from $150 to $165.

Truist Securities Maintains Hold on DaVita, Raises Price Target to $165

Fiduciary Management Q3 2024 Investment Strategy Outlook

Here are the major earnings after the close today

Backs FY24 free cash flow view $950M-$1.2B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T...

DaVita backs FY24 adjusted EPS view $9.25-$10.05, consensus $9.79

DaVita Non-GAAP EPS of $2.59 misses by $0.13, revenue of $3.26B beats by $10M

DaVita down 5% on Q3 bottom line miss

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Reddit (RDDT)&nbsp;up 24.0% S...

Closing Bell Movers: Alphabet up over 5% on Q3 earnings beat

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript

Davita Healthcare ( ($DVA) ) has realeased its Q3 earnings. Here is a breakdown of the information Davita Healthcare presented to its investors. Da...

DaVita Inc. Reports Strong Q3 2024 Performance

In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on DaVita (DVA – Research Report). The company's share...

Truist Financial Remains a Hold on DaVita (DVA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on DaVita (DVA – Research Report), Pfizer (PFE – Rese...

Analysts' Opinions Are Mixed on These Healthcare Stocks: DaVita (DVA), Pfizer (PFE) and Collegium Pharmaceutical (COLL)

ADDDF

ADDYY

AHEXF

AHEXY

AIQUF

AIQUY

ALSN

APAM

ARMK

ATGE

ATOM

BGFV

BMRN

BRDCF

BRDCY

BRSP

BUDFF

CAKE

CARR

CHCT

COLL

CTRE

DANOY

DKILF

DKILY

DLAKF

DLAKY

EADSF

EADSY

ENVX

ETTYF

EXEL

EXLS

EXPGF

EXPGY

FMCQF

FSLR

GOOG

GOOGL

GPDNF

HKHHF

HKHHY

HRZN

ICHGF

IFJPY

IFPJF

ILPT

JBGS

KRYAF

KRYAY

LBTYA

LBTYK

LFUS

LFVN

LSTR

LYSCF

MDLZ

MFIN

MKEWF

MKTAY

NPCPF

NPPHY

NVSEF

ORCL

OTIS

PILBF

PRTS

QRVO

RBGLY

RBGPF

RDDT

RMBS

SAGE

SAPGF

SDXAY

SDXOF

SHLAF

SHLRF

SIEGY

SMAWF

SNAP

SNNUF

STAG

THRY

TRTX

UDMY

VRNS

WERN

WPPGF

Press Releases

DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

DaVita Accelerates Commitment to Community Health with Nationwide Tour

DaVita Prepares Thousands of Dialysis Patients for Hurricane Milton

DaVita Inc. Schedules 3rd Quarter 2024 Investor Conference Call

DaVita Opens its Doors to Anyone in Florida Needing Dialysis After Hurricane Milton

DaVita Appoints Jessica Hergenreter as Chief People Officer

DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program

DaVita Research Centers on Upstream CKD Management; Access & Equity during ASN's Kidney Week 2024

DaVita Emphasizes Commitment to Whole-Person Care with Investment in National Kidney Foundation PEERS Program

Comments

DaVita

DaVita (DVA) Opciones

DaVita (NYSE:DVA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL